Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Total Stockholders Equity : $-0.02 Mil (As of Apr. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Total Stockholders Equity?

Advanced Proteome Therapeutics's Total Stockholders Equity for the quarter that ended in Apr. 2023 was $-0.02 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Advanced Proteome Therapeutics's Book Value per Share for the quarter that ended in Apr. 2023 was $-0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Advanced Proteome Therapeutics's Debt-to-Equity for the quarter that ended in Apr. 2023 was -1.41.

Advanced Proteome Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Advanced Proteome Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Total Stockholders Equity Chart

Advanced Proteome Therapeutics Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Total Stockholders Equity

Get a 7-Day Free Trial

0.56

0.67

0.29

-0.30

1.07

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
Total Stockholders Equity	Get a 7-Day Free Trial															0.72	1.07	0.58	0.36	-0.02

Advanced Proteome Therapeutics (OTCPK:APTCF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Advanced Proteome Therapeutics's Book Value per Share for the quarter that ended in Apr. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-0.022	-	0)	/	41.1271
	=	-0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Advanced Proteome Therapeutics's Debt-to-Equity for the quarter that ended in Apr. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.031	+	0)	/	-0.022
	=	-1.41

Advanced Proteome Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

0E81:Germany APC.H:Canada

Address

8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2

Website

https://www.advancedproteome.com

Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines

From GuruFocus

Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement

By GlobeNewswire GlobeNewswire • 08-23-2018

Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as Chief Executive Officer, President and Director

By GlobeNewswire GlobeNewswire • 06-06-2018